MassAffinity Information

MassAffinity is an interactomics-driven drug discovery company combining a proprietary high-throughput screening platform with expertise across both molecular glues and traditional small molecules. MassAffinity focuses on systematically mapping and modulating protein–protein interactions to unlock complex and previously intractable targets and enabling novel mechanisms of action beyond conventional approaches. MassAffinity’s proprietary drug discovery platform accelerates discovery with label-free, direct detection of drug-target interactions in complex matrices, removing the need for protein purification and supporting highly multiplexed samples. MassAffinity provides a scalable discovery platform and services to partners seeking to de-risk programs against complex biology. In parallel, MassAffinity is advancing an internal pipeline in women’s health, with lead programs in endometriosis focusing on developing first-in-class, disease-modifying therapies. By integrating interactomics with dual-modality discovery, MassAffinity enables systematic access to novel biology and mechanisms, delivering partner-ready opportunities across the full discovery continuum, from target discovery to lead optimization.